Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer

Table 1

Clinical and pathological characteristics of lung cancer patients with c-Met overexpression.

Feature	Patients ()	(%)	c-Met OE ()	%	value
Gender
Male	63	43.2	30	47.6	>0.05
Female	83	56.8	44	53.0
Histopathological subtypes
SCLC	14	9.6	7	50.0	>0.05
NSCLC	132	90.4	67	50.8
Clinical stage
I	32	21.9	11	34.4	<0.05
II	70	47.9	29	41.4
III	28	19.2	20	71.4
IV	16	11.0	14	87.5
Lymph node
Negative	102	69.9	50	49.0	>0.05
Positive	44	30.1	24	54.5
Metastasis
M0	128	87.7	65	50.8	>0.05
M1	18	12.3	9	50.0
Differentiation
Well	28	19.2	9	32.1	<0.01
Moderate	79	54.1	33	41.8
Poor	39	26.7	32	82.1

SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; OE: overexpression.